Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nymox Pharm Corp (NYMX)

Nymox Pharm Corp (NYMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 176,707
  • Shares Outstanding, K 72,719
  • Annual Sales, $ 120 K
  • Annual Income, $ -13,160 K
  • 60-Month Beta 1.31
  • Price/Sales 1,485.72
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.31 +5.19%
on 09/04/20
3.00 -19.00%
on 08/21/20
-0.24 (-8.99%)
since 08/18/20
3-Month
2.31 +5.19%
on 09/04/20
4.23 -42.55%
on 06/26/20
-0.71 (-22.61%)
since 06/18/20
52-Week
1.66 +46.39%
on 03/24/20
4.79 -49.27%
on 06/16/20
+0.44 (+22.11%)
since 09/18/19

Most Recent Stories

More News
Nymox: 2Q Earnings Snapshot

NASSAU, Bahamas (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a loss of $2.9 million in its second quarter.

NYMX : 2.43 (+2.53%)
Nymox Announces $9 Million Registered Direct Offering

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of shares of its common stock...

NYMX : 2.43 (+2.53%)
Nymox Announces Updates in Regulatory Submissions For Fexapotide Treatment For Prostate Enlargement

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is very pleased to report that key steps in its regulatory submission preparations have been completed and the project is firmly on-track. The majority of...

NYMX : 2.43 (+2.53%)
Nymox: 1Q Earnings Snapshot

ST. LAURENT, Quebec (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Thursday reported a loss of $2.6 million in its first quarter.

NYMX : 2.43 (+2.53%)
Nymox Announces Important New Patent Developments

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the recent allowances of 4 new different US and international patents concerning the Company's prostate enlargement and prostate cancer...

NYMX : 2.43 (+2.53%)
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial...

NYMX : 2.43 (+2.53%)
Nymox Announces New Appointment of Russell Thomson Ph.D. as Nymox Vice President of Quality and Regulatory Affairs

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the new appointment of Russell I. Thomson PhD, FRSC to the position of Nymox Vice President of Quality and Regulatory Affairs. Dr...

NYMX : 2.43 (+2.53%)
Nymox Provides Update on Current Corporate Activities and Milestones

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current January 2020 update on several important corporate activities and achievements since the last update in October 2019.

NYMX : 2.43 (+2.53%)
Nymox Announces New Peer Review Article on Fexapotide Pharmaco-Ablation Experimental Studies Published in Research and Reports in Urology

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to report a new peer review research report has been published on experimental studies of the Company's Fexapotide Triflutate treatment for prostate...

NYMX : 2.43 (+2.53%)
Nymox: 3Q Earnings Snapshot

ST. LAURENT, Quebec (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Wednesday reported a loss of $2.5 million in its third quarter.

NYMX : 2.43 (+2.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Trade NYMX with:

Business Summary

Nymox Pharmaceutical Corporation is engaged in the research and development of drugs and diagnostic products. The company offers products such as AlzheimAlert, NicAlert and TobacAlert tests. It markets its products primarily in the United States, Canada, and Europe. Nymox Pharmaceutical Corporation is...

See More

Key Turning Points

2nd Resistance Point 2.53
1st Resistance Point 2.48
Last Price 2.43
1st Support Level 2.36
2nd Support Level 2.29

See More

52-Week High 4.79
Fibonacci 61.8% 3.59
Fibonacci 50% 3.22
Fibonacci 38.2% 2.86
Last Price 2.43
52-Week Low 1.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar